Cargando…

Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats

BACKGROUND: This study aims at characterizing the in vitro metabolism of cryptolepine using human and rat hepatocytes, identifying metabolites in rat plasma and urine after a single cryptolepine dose, and evaluating the single-dose oral and intravenous pharmacokinetics of cryptolepine in male Spragu...

Descripción completa

Detalles Bibliográficos
Autores principales: Forkuo, Arnold Donkor, Ansah, Charles, Pearson, David, Gertsch, Werner, Cirello, Amanda, Amaral, Adam, Spear, Jaimie, Wright, Colin W., Rynn, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741962/
https://www.ncbi.nlm.nih.gov/pubmed/29273084
http://dx.doi.org/10.1186/s40360-017-0188-8
_version_ 1783288291398778880
author Forkuo, Arnold Donkor
Ansah, Charles
Pearson, David
Gertsch, Werner
Cirello, Amanda
Amaral, Adam
Spear, Jaimie
Wright, Colin W.
Rynn, Caroline
author_facet Forkuo, Arnold Donkor
Ansah, Charles
Pearson, David
Gertsch, Werner
Cirello, Amanda
Amaral, Adam
Spear, Jaimie
Wright, Colin W.
Rynn, Caroline
author_sort Forkuo, Arnold Donkor
collection PubMed
description BACKGROUND: This study aims at characterizing the in vitro metabolism of cryptolepine using human and rat hepatocytes, identifying metabolites in rat plasma and urine after a single cryptolepine dose, and evaluating the single-dose oral and intravenous pharmacokinetics of cryptolepine in male Sprague Dawley (SD) rats. METHODS: The in vitro metabolic profiles of cryptolepine were determined by LC-MS/MS following incubation with rat and human hepatocytes. The in vivo metabolic profile of cryptolepine was determined in plasma and urine samples from Sprague Dawley rats following single-dose oral administration of cryptolepine. Pharmacokinetic parameters of cryptolepine were determined in plasma and urine from Sprague Dawley rats after single-dose intravenous and oral administration. RESULTS: Nine metabolites were identified in human and rat hepatocytes, resulting from metabolic pathways involving oxidation (M2-M9) and glucuronidation (M1, M2, M4, M8, M9). All human metabolites were found in rat hepatocyte incubations except glucuronide M1. Several metabolites (M2, M6, M9) were also identified in the urine and plasma of rats following oral administration of cryptolepine. Unchanged cryptolepine detected in urine was negligible. The Pharmacokinetic profile of cryptolepine showed a very high plasma clearance and volume of distribution (Vss) resulting in a moderate average plasma half-life of 4.5 h. Oral absorption was fast and plasma exposure and oral bioavailability were low. CONCLUSIONS: Cryptolepine metabolism is similar in rat and human in vitro with the exception of direct glucuronidation in human. Clearance in rat and human is likely to include a significant metabolic contribution, with proposed primary human metabolism pathways hydroxylation, dihydrodiol formation and glucuronidation. Cryptolepine showed extensive distribution with a moderate half-life.
format Online
Article
Text
id pubmed-5741962
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-57419622018-01-03 Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats Forkuo, Arnold Donkor Ansah, Charles Pearson, David Gertsch, Werner Cirello, Amanda Amaral, Adam Spear, Jaimie Wright, Colin W. Rynn, Caroline BMC Pharmacol Toxicol Research Article BACKGROUND: This study aims at characterizing the in vitro metabolism of cryptolepine using human and rat hepatocytes, identifying metabolites in rat plasma and urine after a single cryptolepine dose, and evaluating the single-dose oral and intravenous pharmacokinetics of cryptolepine in male Sprague Dawley (SD) rats. METHODS: The in vitro metabolic profiles of cryptolepine were determined by LC-MS/MS following incubation with rat and human hepatocytes. The in vivo metabolic profile of cryptolepine was determined in plasma and urine samples from Sprague Dawley rats following single-dose oral administration of cryptolepine. Pharmacokinetic parameters of cryptolepine were determined in plasma and urine from Sprague Dawley rats after single-dose intravenous and oral administration. RESULTS: Nine metabolites were identified in human and rat hepatocytes, resulting from metabolic pathways involving oxidation (M2-M9) and glucuronidation (M1, M2, M4, M8, M9). All human metabolites were found in rat hepatocyte incubations except glucuronide M1. Several metabolites (M2, M6, M9) were also identified in the urine and plasma of rats following oral administration of cryptolepine. Unchanged cryptolepine detected in urine was negligible. The Pharmacokinetic profile of cryptolepine showed a very high plasma clearance and volume of distribution (Vss) resulting in a moderate average plasma half-life of 4.5 h. Oral absorption was fast and plasma exposure and oral bioavailability were low. CONCLUSIONS: Cryptolepine metabolism is similar in rat and human in vitro with the exception of direct glucuronidation in human. Clearance in rat and human is likely to include a significant metabolic contribution, with proposed primary human metabolism pathways hydroxylation, dihydrodiol formation and glucuronidation. Cryptolepine showed extensive distribution with a moderate half-life. BioMed Central 2017-12-22 /pmc/articles/PMC5741962/ /pubmed/29273084 http://dx.doi.org/10.1186/s40360-017-0188-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Forkuo, Arnold Donkor
Ansah, Charles
Pearson, David
Gertsch, Werner
Cirello, Amanda
Amaral, Adam
Spear, Jaimie
Wright, Colin W.
Rynn, Caroline
Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats
title Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats
title_full Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats
title_fullStr Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats
title_full_unstemmed Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats
title_short Identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in Sprague Dawley rats
title_sort identification of cryptolepine metabolites in rat and human hepatocytes and metabolism and pharmacokinetics of cryptolepine in sprague dawley rats
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741962/
https://www.ncbi.nlm.nih.gov/pubmed/29273084
http://dx.doi.org/10.1186/s40360-017-0188-8
work_keys_str_mv AT forkuoarnolddonkor identificationofcryptolepinemetabolitesinratandhumanhepatocytesandmetabolismandpharmacokineticsofcryptolepineinspraguedawleyrats
AT ansahcharles identificationofcryptolepinemetabolitesinratandhumanhepatocytesandmetabolismandpharmacokineticsofcryptolepineinspraguedawleyrats
AT pearsondavid identificationofcryptolepinemetabolitesinratandhumanhepatocytesandmetabolismandpharmacokineticsofcryptolepineinspraguedawleyrats
AT gertschwerner identificationofcryptolepinemetabolitesinratandhumanhepatocytesandmetabolismandpharmacokineticsofcryptolepineinspraguedawleyrats
AT cirelloamanda identificationofcryptolepinemetabolitesinratandhumanhepatocytesandmetabolismandpharmacokineticsofcryptolepineinspraguedawleyrats
AT amaraladam identificationofcryptolepinemetabolitesinratandhumanhepatocytesandmetabolismandpharmacokineticsofcryptolepineinspraguedawleyrats
AT spearjaimie identificationofcryptolepinemetabolitesinratandhumanhepatocytesandmetabolismandpharmacokineticsofcryptolepineinspraguedawleyrats
AT wrightcolinw identificationofcryptolepinemetabolitesinratandhumanhepatocytesandmetabolismandpharmacokineticsofcryptolepineinspraguedawleyrats
AT rynncaroline identificationofcryptolepinemetabolitesinratandhumanhepatocytesandmetabolismandpharmacokineticsofcryptolepineinspraguedawleyrats